Skip to main content
EWTX logo

EWTX · Edgewise Therapeutics, Inc. · Metrics

Track EWTX — free
$39.91 -1.27 (-3.07%) At close · Nov 20
Market Cap
$4.37B
Shares
109.48M
Volume · Nov 20 1.19M Avg daily vol (3M) 1.53M

EWTX metrics

72 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$39.91
Market cap
$4.37B

Price action

23 metrics
Price change (1W)
-13.1%
Price change (30D)
+1.5%
Price change (3M)
-9.7%
Price change (6M)
+22.0%
Price change (YTD)
+60.8%
Price change (1Y)
+79.3%
Trailing year
Price change (5Y)
+100.1%
52-week high
$48.74
52-week low
$20.94
Change from 52-week high
-18.1%
Change from 52-week low
+90.6%
Annualized volatility
72.7%
Annualized volatility (3M)
54.1%
Implied volatility (30D)
97.4%
IV rank (1Y)
25.8
IV percentile (1Y)
77.3
Beta
1.2
RSI (14D)
44.2
Price vs SMA 50
-3.0%
Price vs SMA 200
+6.9%
Avg volume (3M)
1.53M
Relative volume
0.8
Average dollar volume
$63.79M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
109.48M

Valuation

12 metrics
P / E (TTM)
4.9
Trailing earnings · reciprocal yield 20.5%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
2.7
reciprocal yield 37.4%
FCF yield
-4.6%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
23.1%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2024-05-13

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$218.18M
Net income (TTM)
$1.01B
Trailing 12 months
Diluted EPS (TTM)
$8.19
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-1.99
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$8.18
Operating cash flow per diluted share (TTM)
$-1.80
Free cash flow per diluted share (TTM)
$-1.81
Capital expenditures per diluted share (TTM)
$0.00
R&D per diluted share (TTM)
$1.51
Stock compensation per diluted share (TTM)
$0.33
Book value per share
$14.91

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+14.6%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
61.8%
Return on assets
56.7%
Debt / equity
0.0
Current ratio
12.3
EBITDA (TTM)
—
Free cash flow (TTM)
−$202.28M
Quick ratio
12.3
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$68.68M
Latest balance sheet
Cash & equivalents
$68.68M
Total assets
$1.78B
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$201.90M
Capital expenditures (TTM)
$382,000
R&D (TTM)
$165.37M
SG&A (TTM)
—
Stock compensation (TTM)
$36.52M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
253
13F filer change QoQ
+27
Institutional ownership
114.2%
Conviction holders (share of 13F filers)
5.9%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+4.7%
Holder tenure
14.0
Price vs estimated holder cost
+63.4%

Ownership (registered funds)

1 metrics
Index-fund ownership
10.3%

Short interest

3 metrics
Short interest
11.6%
Latest settlement · 9.6 days to cover
Days to cover
9.6d
Short-squeeze score
72 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$240,627
Insider-sentiment score
45 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1710072 CUSIP 28036F105 13F (30d) 260 filings 237 filers Visit website Investor relations